Translational Research

Target Immune Therapy to Cancer Cells

Company Overview Innovation: Targeting Immune Engagement Targeted Cancer(s): Gastrointestinal cancers, including pancreas, stomach, liver and bowel. Scientific Leadership/Leadership: Prof. John Luk, DMedSc., EMBA, CEO and Founder Dr. Dennis Wong, MD, Global Clinical Officer Mr. David Lam, Head of Corporate Finance Stage of Company: Set to initiate clinical study of our…...

Read more

YIV-906: Therapeutics—first-in-class botanical cancer platform drug

Ongoing since 2020 Company Overview Innovation: Therapeutics—first-in-class botanical cancer platform drug Targeted Cancer(s): Liver cancer Scientific Leadership: Yung-Chi Cheng, Ph.D.; Shwu-Huey Liu, Ph.D. Stage of Project: Phase II clinical trial about to commence; orphan drug designations granted by the U.S. Food and Drug Administration (FDA) Opportunity YIV-906 is a botanical cancer drug that can…...

Read more

DotBio: Multi-functional antibodies to target cancer on multiple fronts

Advanced cancers typically suppress the immune response by multiple mechanisms. By carefully engineering multi-functional antibody therapies, there is the potential for more effective treatment....

Read more

Determining the Risk of Hereditary Breast and Ovarian Cancer (HBOC) in China

Understanding the risk of breast cancer in the Chinese population is very important due to the exponential increase in incidence......

Read more

Gastric Cancer Research

Gastric cancer is the fourth most common cancer and the second leading cause of cancer death worldwide....

Read more

Tissue Bank Consortium in Asia

Integrating international resources to promote collaboration and accelerate cancer research...

Read more